News

Silvio Nunes Silvio Nunes

Neurosom is very grateful to be chosen as a finalist for the Angel Oregon Life & BioScience (AOBIO) investment program.

This incredible platform run by @Oregon Entrepreneur Network has given us much guidance this year in the form of regular workshop meetings with successful PNW CEOs, investors, and leaders in the business community, as well as opportunities to perfect our networking and pitching strategies. We have gained much insight and focus from this opportunity and have also enjoyed meeting this lovely group of supportive people. See OEN announcement: https://lnkd.in/gV5DAjtj

Read More
Silvio Nunes Silvio Nunes

Neurosom is an Early Growth Finalist in the Bend Venture Conference

As we approach the Bend Venture Conference on October 16 and 17, Neurosom™ is gearing up to share our mission to optimize sleep and reduce the risk of dementia. Our company was founded by neuroscientists who pioneered innovations in brain monitoring. Through studying the brain, scientists learned that deep sleep is essential for clearing toxic proteins from the brain through the glymphatic system, the brain’s waste removal pathway. When deep sleep is disrupted, glymphatic clearance fails, memory suffers, and neurodegeneration accelerates. 

Read More
Silvio Nunes Silvio Nunes

Neurosom is a finalist for the Early Stage Company Category at the Bend Venture Conference (BVC)!

Last night at the "On the Road to BVC" event at Worthy Brewery in Bend, Viral joined other company founders to deliver a 3 minute pitch to judges and a live audience. When the votes were counted, we were grateful to be chosen among so many other great Oregon entrepreneurs. We look forward to having the opportunity to share our vision for Sleep Therapy and reducing dementia risk at the Bend Venture Conference, which happens October 16-17 in beautiful downtown Bend.

Read More
Silvio Nunes Silvio Nunes

Neurosom is honored to be chosen as a semi-finalist in the Bend Venture Conference Early Growth Category.

Join us for the PubTalk event this Thursday, September, 25th at Worthy Brewing in Bend, OR, on the road to BVC, where our CEO Viral Sheth will join other competitors in delivering a three-minute pitch to a live audience. The audience, along with a panel of judges, will decide who gets to present at the Tower Theater during the Bend Venture Conference October 16-17, 2025.

Read More
Silvio Nunes Silvio Nunes

Better Sleep Could Help Your Brain Flush Out Dementia-Linked Toxins

New informative article: "Better Sleep Could Help Your Brain Flush Out Dementia-Linked Toxins". This well-written description of metabolic waste clearance, recently published in Science Direct, gives readers a deep dive into how improving sleep can reduce the risk for Dementia.

Read More
Silvio Nunes Silvio Nunes

A new study published in Nature highlights the feasibility of predicting cognitive decline with a one-channel EEG device and AI.

Scientists studied EEG patterns in elderly subjects and, with the assistance of AI, found a correlation between irregular EEG activity and mild cognitive impairment. The future utility of EEG in the detection of neurodegenerative illness opens an area of keen interest, as current diagnostic methods often do not detect MCI until it has progressed to dementia. Read the article: https://lnkd.in/eNuMyiwj

Read More
Silvio Nunes Silvio Nunes

Register for our free webinar: "Use FLOW in your lab to convert scripts into a reproducible, single-click workflow"

Register at: https://lnkd.in/gB7-bhSc for tomorrow's webinar - May 20th, 8 am PST, 11 am EST, "Use FLOW in your lab to convert scripts into a reproducible, single-click workflow", Featuring Dr. Jhunlyn Lorenzo, Post Doctoral Researcher at the Cognitive Neuroimaging lab (UNICOG) and Neurospin (France), and Roma Shusterman, our Chief Technology Officer at BEL. They will demonstrate how the NeuroSpin lab developed a MATLAB-based EEG analysis pipeline (APICE) and used FLOW to containerize it into a reproducible, single-click workflow. This 45-minute webinar includes a live demo and 10-15 minutes of Q&A at the end.

Read More